Kolexia
Grob Jean-Jacques Dermatologie
Grob Jean-Jacques
Dermatologie
Hôpital La Timone
Marseille, France
601 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Mélanome Tumeurs cutanées Carcinomes Métastase tumorale Tumeurs du cerveau Carcinome basocellulaire Carcinome épidermoïde Récidive tumorale locale Effets secondaires indésirables des médicaments

Collaborateurs

Voir plus
Robert Caroline
Robert Caroline
Gustave-Roussy, Villejuif, France
Lebbe Celeste
Lebbe Celeste
Hôpital Saint-Louis, Paris, France
Gaudy-Marqueste Caroline
Gaudy-Marqueste Caroline
Hôpital La Timone, Marseille, France
Richard Marie Aleth
Richard Marie Aleth
Hôpital La Timone, Marseille, France

Industries

Voir plus
Novartis
51 collaboration(s)
Dernière en 2023
BMS
28 collaboration(s)
Dernière en 2023
MSD
18 collaboration(s)
Dernière en 2023
Pierre Fabre
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587): A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Essai Clinique (Merck & Co.)   20 mars 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   07 mars 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Future oncology (London, England)   23 février 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Clinical and translational science   23 février 2024
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200): A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Essai Clinique (Emd Serono)   14 février 2024
High anti-topoisomerase-1 autoantibodies levels are associated with the extension of skin fibrosis and vascular progression in patients with systemic sclerosis.
La Revue de medecine interne   13 février 2024
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716): Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Essai Clinique (Merck & Co.)   08 février 2024
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors: A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Essai Clinique (BMS)   06 février 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
European journal of cancer (Oxford, England : 1990)   01 février 2024
COMBI-i: A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Essai Clinique (Novartis)   30 janvier 2024